Skip to content
CancerIndex

Publication

Potential Resistance to Oxaliplatin-Based Regimens in Gastric Cancer Patients with ERBB2 R678Q Mutation: Evidence from a National Genomic Database.

Authors not recorded

Curr Issues Mol Biol2025PMID 40699829PMC12192524stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
40699829
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
ERBB2 R678Q3
NivolumabGastric AdenocarcinomaPredictiveBDoes Not Support Resistance2accepted
EID13140

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q did not show a significant association with resistance to nivolumab-contain… (full text at CIViC)

PMID 40699829 · Suzuki et al., 2025 · Open in CIViC

civic
OxaliplatinGastric AdenocarcinomaPredictiveBSupports Resistance3accepted
EID13138

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q was associated with reduced response to oxaliplatin-based regimens compared… (full text at CIViC)

PMID 40699829 · Suzuki et al., 2025 · Open in CIViC

civic
RamucirumabGastric AdenocarcinomaPredictiveBDoes Not Support Resistance2accepted
EID13139

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q did not show a significant association with resistance to ramucirumab-conta… (full text at CIViC)

PMID 40699829 · Suzuki et al., 2025 · Open in CIViC

civic